Medicare to Slash Out-of-Pocket Costs for High-Cost Medications by 2026
Expect significant reductions in out-of-pocket costs for Medicare enrollees by 2026, changing drug prices under the Inflation Reduction Act. Learn more!
Medicare Part D Donut Hole Eliminated: New Coverage Structure in 2025
Medicare Part D's coverage gap, known as the Donut Hole, is eliminated in 2025 with a new three-phase benefit and $2,000 out-of-pocket cap, enhancing cost predictability and managing prescription drug expenses for beneficiaries.
U.S. Expands Medicare Coverage and Negotiates Lower Prices for Weight-Loss Drugs
The Trump administration announces agreements with Eli Lilly and Novo Nordisk to lower prices and expand Medicare coverage for weight-loss drugs like Wegovy and Zepbound, effective 2026.
Insilico Medicine's Major Listing Boosts AI Innovation in Drug Discovery
Discover how Insilico Medicine's IPO on the Hong Kong Exchange is revolutionizing drug discovery with AI, drawing significant investor interest and market confidence.
Pharma Firms Slash Medicare Drug Prices in Trump Administration Deal
Pharmaceutical companies agree to significant Medicare drug price cuts under Trump administration, projecting billions in savings with impacts on Medicare Part D and drug affordability.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
Novo Nordisk, Eli Lilly Cut GLP-1 Prices for Expanded Medicare Market Access
Novo Nordisk and Eli Lilly agree to lower GLP-1 drug prices in exchange for expanded Medicare and Medicaid coverage, marking a major shift in U.S. drug pricing and access.
Impact of MFN Drug Pricing Policy on Medicare Part D Deadline Approaches
The looming deadline for drugmakers to comply with the Most Favored Nation drug pricing policy raises concerns over potential disruptions to Medicare Part D, highlighting regulatory and market risks for U.S. drug pricing and federal entitlement programs.
GLP-1 Drugs Pose Coverage Challenges Amid Proven Health Benefits
Analysis finds GLP-1 drugs like semaglutide offer real health benefits but raise insurance coverage and cost challenges amid growing demand in the U.S. market.
FTC Warns Healthcare Employers on Noncompetes; Industry Sees Rising Unionization and Tech Advances
FTC cautions healthcare employers on noncompetes. Rising physician unionization, Medicare Plan Finder updates, Kaiser-Renown joint venture, AI tools, FDA drug approvals, and robotic intubation device mark key healthcare industry trends in 2025.